The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

Ertugliflozin is a highly selective and potent inhibitor of the sodium‐glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus. The glycemic efficacy of sodium‐glucose cotransporter 2 inhibitors such as ertugliflozin depends on glucose filtration through the kidney. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655776/
https://www.ncbi.nlm.nih.gov/pubmed/28703316
http://dx.doi.org/10.1002/jcph.955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655776/
https://www.ncbi.nlm.nih.gov/pubmed/28703316
http://dx.doi.org/10.1002/jcph.955

Ejemplares similares